Comparison of treatment routine using aflibercept: Strict vs. relaxed retreatment regimen (TOLERANT study)-A non-inferiority, randomized controlled trial., PMID:40326420
Different clinical presentations of persistent placoid maculopathy: a case series., PMID:40329229
Uncommon Therapeutic Approaches for Patients with Recurrent Central Serous Chorioretinopathy: case report and literature review., PMID:40330964
Endophthalmitis following intravitreal injections at a tertiary center: real-life data on incidence, risk factors, management strategies, and visual outcomes., PMID:40335933
Improved functional and morphological outcomes with faricimab in nAMD eyes with poor response to prior intravitreal anti-VEGF therapy., PMID:40338383
Plain-language commentary: 2-year findings from the FIREFLEYE next study looking at how well aflibercept injected into affected eyes in babies with retinopathy of prematurity works and how safe it is compared with laser treatment., PMID:40342575
Anti-VEGF drugs compared with laser photocoagulation for the treatment of diabetic retinopathy: a systematic review and economic analysis., PMID:40347224
Comprehensive multi-omics and pharmacokinetics reveal sclareol's role in inhibiting ocular neovascularization., PMID:40347925
Long-term outcomes of the observe-and-plan regimen in treating neovascular age-related macular degeneration: a retrospective real-life analysis., PMID:40348918
Visual outcome following initiation of first injection versus after three monthly doses of aflibercept 2 mg for treatment naïve age-related macular degeneration to inform clinical trial designs: PRECISE Report No. 6., PMID:40355704
Bilateral Idiopathic Multifocal Pigment Epithelial Detachments: A Case Series and Review of Literature., PMID:40359333
Silicone oil microdroplets from syringes with intravitreal anti-vascular endothelial growth factor and complement inhibitor injections., PMID:40359347
Faricimab Reverts VEGF-A165-Induced Impairment of the Barrier Formed by Retinal Endothelial Cells., PMID:40362554
Sustainable Practices in Anti-VEGF Therapy: A 15-Year Bibliometric Analysis of Ranibizumab for Age-Related Macular Degeneration., PMID:40365539
Recurrence of Macular Edema in Branch Retinal Vein Occlusion-A Comparison of Aflibercept and Ranibizumab in a Randomized Trial., PMID:40373873
Successful use of aflibercept for high cardiac output in hereditary hemorrhagic telangiectasia after failure of pazopanib and bevacizumab therapy., PMID:40379104
Prospective evaluation of soluble CD14 as a biomarker following five aflibercept treatments in diabetic macular edema., PMID:40379891
Socioeconomic Disparities in Intravitreal Injection Use and Anti-VEGF Agent Selection: Aflibercept/Ranibizumab Versus Bevacizumab., PMID:40383690
Aflibercept for the treatment of pigmentary retinopathy in Kearns-Sayre syndrome?, PMID:40389721
Response: Aflibercept for the treatment of pigmentary retinopathy in Kearns-Sayre Syndrome?, PMID:40392487
Twelve-Month Outcomes of Faricimab for Patients with Sub-Optimally Responsive Diabetic Macular Oedema: A Retrospective Single-Centre Study., PMID:40396158
Successful Response to Intravitreal Faricimab Injections in a Case of Neovascular Age-Related Macular Degeneration in Vitrectomized Eyes., PMID:40400877
Effectiveness and safety of anti-vascular endothelial growth factor therapies for macular edema in retinal vein occlusion: A systematic review and network meta-analysis of randomized controlled trials., PMID:40419166
Real-Life Treatment Intervals and Morphological Outcomes Following the Switch to Faricimab Therapy in Neovascular Age-Related Macular Degeneration., PMID:40423060
Oral lamivudine in diabetic macular edema: A randomized, double-blind, placebo-controlled clinical trial., PMID:40436012
Managing Choroidal Neovascularization in Pseudoxanthoma Elasticum: Outcomes of Vitrectomy and Intravitreal Ranibizumab/Aflibercept Therapy-A Case Report., PMID:40438152
Deep learning-assisted analysis of biomarker changes after increase of dosing from aflibercept 2 mg to 8 mg in therapy-resistant neovascular age-related macular degeneration., PMID:40451292
Anti-VEGF Agents Clearance Through the Aqueous Outflow Pathway in a Rat Model., PMID:40455045
Association between intravitreal anti-vascular endothelial growth factor agents and hypertension: a meta-analysis., PMID:40456283
Author Correction: Effects of switching from intravitreal injection of aflibercept to faricimab on ocular blood flow in patients with diabetic macular edema., PMID:40456888
Extended duration of VEGF inhibition with aflibercept 8 mg: the role of reduced ocular clearance., PMID:40456958
Corrigendum: Efficacy and safety of intravitreal injection of aflibercept biosimilar for treating diabetic macular edema., PMID:40458651
TALON Phase IIIb Study: 32 Week Primary Results of Brolucizumab Using Treat and Extend for Neovascular Age Related Macular Degeneration., PMID:40466770
A swept-source optical coherence tomography study of the spectrum of laser pointer maculopathy., PMID:40474312
Intravitreal anti-vascular endothelial growth factor injections and risks of stroke in patients with neovascular age-related macular degeneration-A registry-based cohort study., PMID:40481786
Anti-VEGFs for Diabetic Macular Oedema: Analysis of Efficacy, Safety, and Cost of More Durable Therapies from a Dutch Societal Perspective., PMID:40481910
Usage of brolucizumab as treatment for wet age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV): A narrative review., PMID:40489855
Feedback regulation between histone lactylation and ALKBH3-mediated glycolysis regulates age-related macular degeneration pathology., PMID:40493193
Effect of Faricimab versus Aflibercept on Hyperreflective Foci in Patients with Diabetic Macular Edema from the YOSEMITE/RHINE Trials., PMID:40496217
A Prospective Observational Study of Intravitreal Aflibercept in Retinal Vein Occlusion with Initially Good Visual Acuity., PMID:40499162
Efficacy of switching from existing anti-vascular endothelial growth factor drugs to ranibizumab biosimilar in neovascular age-related macular degeneration., PMID:40500585
Factors determining timing of first recurrence after three loading aflibercept injections in newly diagnosed neovascular age-related macular degeneration., PMID:40504424
Six-year findings of polypoidal choroidal vasculopathy in the EVEREST II study: Japanese subgroup analysis., PMID:40504425
A randomized, double-masked parallel-group, multicenter clinical study evaluating the efficacy and safety of the biosimilar candidate AVT06 compared to the reference product aflibercept in participants with neovascular age-related macular degeneration., PMID:40512025
Real-World 5-Year Outcomes of Age-Related Macular Degeneration with Bevacizumab as First-Line Anti-VEGF., PMID:40517351
Age-independent anti-angiogenic therapy for choroidal neovascularization by targeting secretogranin III., PMID:40518488
Interventions for central serous chorioretinopathy: a network meta-analysis., PMID:40522203
Intraocular inflammation following intravitreal injections of anti-vascular endothelial growth factor drugs., PMID:40522452
Clinical Trials of Aflibercept Biosimilars: A Review., PMID:40526023
Faricimab for treatment-resistant choroidal neovascularization (CNV) in neovascular age-related macular degeneration (nAMD): seven-months results using artificial intelligence and OCTA., PMID:40528210
Aflibercept: an update on recent milestones achieved, PMID: 25588083
Aflibercept (eylea) for age-related macular degeneration, PMID: 22354219
PHARMACOKINETIC STUDY OF INTRAVITREAL AFLIBERCEPT IN HUMANS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION, PMID: 31145389
Aflibercept regulates retinal inflammation elicited by high glucose via the PlGF/ERK pathway, PMID: 31351870
Ranibizumab and aflibercept for the treatment of wet age-related macular degeneration, PMID: 26076760
HAWK and HARRIER: Ninety-Six-Week Outcomes from the Phase 3 Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration, PMID: 32574761
INTRAVITREAL AFLIBERCEPT AND RANIBIZUMAB INJECTIONS FOR TYPE 3 NEOVASCULARIZATION, PMID: 28984737
Evaluation of aflibercept in the treatment of metastatic colorectal cancer, PMID: 25152076
Aflibercept a new target therapy in cancer treatment: a review, PMID: 26224565
Ziv-aflibercept: a novel angiogenesis inhibitor for the treatment of metastatic colorectal cancer, PMID: 24128964
Aflibercept for intravitreal injection: in neovascular age-related macular degeneration, PMID: 23038609
Intravitreal aflibercept injection in Indian eyes with retinopathy of prematurity, PMID: 31124509
Switching between ranibizumab and aflibercept for the treatment of neovascular age-related macular degeneration, PMID: 29476754
Aflibercept for age-related macular degeneration: a game-changer or quiet addition?, PMID: 22813448
A preclinical and clinical review of aflibercept for the management of cancer, PMID: 22264850
Influence of aflibercept on platelet activation profile, PMID: 29908884
Aflibercept for the treatment of diabetic macular edema, PMID: 26907516
Aflibercept in age-related macular degeneration: evaluating its role as a primary therapeutic option, PMID: 28548650
Transport and fate of aflibercept in VEGF-A 165-challenged retinal endothelial cells, PMID: 32712182
Aflibercept in the Treatment of Diabetic Macular Edema: A Review and Consensus Paper, PMID: 29077188
Intravitreal Aflibercept in Diabetic Macular Edema: Long-Term Outcomes, PMID: 28427067
Aflibercept: A Review of Its Use in Diabetic Macular Oedema, PMID: 26056030
Ziv-aflibercept (Zaltrap) for the treatment of metastatic colorectal cancer, PMID: 24259608
Aflibercept: A Review in Macular Oedema Secondary to Branch Retinal Vein Occlusion, PMID: 28365905
Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD, PMID: 25001321
Aflibercept (VEGF-TRAP): the next anti-VEGF drug, PMID: 21999177
Potential of subconjunctival aflibercept in treating choroidal neovascularization, PMID: 32795527
Aflibercept: A Review of Its Use in the Management of Diabetic Eye Complications, PMID: 27166390
Intravitreal Ziv-Aflibercept: Clinical Effects and Economic Impact, PMID: 28971631
A Randomized, Double-Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Patients with Visual Impairment due to Diabetic Macular Edema (KITE), PMID: 32131127
Real-World Effectiveness and Real-World Cost-Effectiveness of Intravitreal Aflibercept and Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Real-World Studies, PMID: 31728825
Aflibercept: A Review in Metastatic Colorectal Cancer, PMID: 26220913
Change in Diabetic Retinopathy Through 2 Years: Secondary Analysis of a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab, PMID: 28448655
Intravitreal aflibercept and ranibizumab for pachychoroid neovasculopathy, PMID: 30765771
Aflibercept: A review of its effect on the treatment of exudative age-related macular degeneration, PMID: 30813810
Aflibercept, PMID: 22460118
HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration, PMID: 30986442
Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen, PMID: 22949147
The cost-effectiveness of bevacizumab, ranibizumab and aflibercept for the treatment of age-related macular degeneration-A cost-effectiveness analysis from a societal perspective, PMID: 29772018
Aflibercept, PMID: 23444216
Ranibizumab or Aflibercept for Diabetic Macular Edema: Comparison of 1-Year Outcomes from the Fight Retinal Blindness! Registry, PMID: 31932092
Nephrotoxicity Associated with Novel Anticancer Agents (Aflibercept, Dasatinib, Nivolumab): Case Series and Nephrological Considerations, PMID: 32664269
Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial, PMID: 29392288
Brolucizumab Versus Aflibercept in Participants with Neovascular Age-Related Macular Degeneration: A Randomized Trial, PMID: 28551167
SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB, PMID: 28106709
Aflibercept for neovascular age-related macular degeneration, PMID: 26857947
Intravitreal Ziv-Aflibercept: A Comprehensive Review, PMID: 31314638
Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema: recent clinically relevant findings from DRCR.net Protocol T, PMID: 28837425
Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial, PMID: 26935357
Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration, PMID: 23084240
For research use only. Not for human or drug use.
